Proper functioning of the mammalian nervous system depends on a specific
wiring pattern determined by a developmental program. This program
directs how neurons divide at early stages, migrate to their final
destination, outgrow cell processes and, finally, establish synapses with
other neurons or a distinct target cell. A significant number of human
diseases occur as a result of an aberrant completion of this
developmental program. Many of these diseases, including Down's
Syndrome, several forms of congenital mental retardation,
phenylketonuria, malnutrition and schizophrenia are characterized by
neurons with an alteration in the normal structure and number of
neurites. Microtubules and microtubule-associated proteins and enzymes
are known to play a crucial role in the development of normal wiring
patterns in the nervous system by taking part in the extension of
neuronal processes. Our laboratory is focused on the role of a specific
microtubule-associated enzyme, dynamin, in the extension of neuronal
processes. Dynamin is a microtubule-activated GTPase that binds and
cross-links microtubules in vitro in a nucleotide-dependent manner and
therefore has been proposed to act as a microtubule-based motor in vivo.
We have made important preliminary observations which indicate that 1)
dynamin is essential for neurite formation and 2) dynamin is localized
at the neuronal growth cone. In addition, we have cloned a novel dynamin
gene encoding a second isoform expressed in rat brain. From these
studies, we hypothesize that dynamin contributes to the formation of
neurites during development by: a) maintaining the normal structure of
neuronal processes through cross-linking and positioning microtubules in
the neurite and b) participating in the endocytic recycling of proteins
which are important for neurite outgrowth. We have designed experiments
to correlate the level of dynamin with the formation of neurites in both
hippocampal neurons and PC12 cells developing in vitro. Furthermore,
additional studies are aimed to alter the expression of dynamin using
antisense technology and determine whether a reduced level of this
protein impairs neurite outgrowth. We will use state-of-the-art video
and electron microscopy in combination with molecular biological
techniques to determine the integrity of the microtubule network and
endocytic vesicular transport pathway in the dynamin minus neurons. To
our knowledge, this is the first study which has provided insight into
the in vitro role of dynamin in neuronal development. We are optimistic
that a detailed characterization of the mechanisms involved in neurite
formation will help us better understand many mental diseases.
National Institute of Neurological Disorders and Stroke
CFDA Code
DUNS Number
006471700
UEI
Y2K4F9RPRRG7
Project Start Date
01-May-1994
Project End Date
30-April-1999
Budget Start Date
01-May-1995
Budget End Date
30-April-1996
Project Funding Information for 1995
Total Funding
$99,175
Direct Costs
$64,820
Indirect Costs
$34,355
Year
Funding IC
FY Total Cost by IC
1995
National Institute of Neurological Disorders and Stroke
$99,175
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R29NS032882-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R29NS032882-02
Patents
No Patents information available for 5R29NS032882-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R29NS032882-02
Clinical Studies
No Clinical Studies information available for 5R29NS032882-02
News and More
Related News Releases
No news release information available for 5R29NS032882-02
History
No Historical information available for 5R29NS032882-02
Similar Projects
No Similar Projects information available for 5R29NS032882-02